FBR Capital Maintains a 'Market Perform' on Quality Systems (QSII); Fiscal 4Q11 Precall: Stimulus Helps Deliver Strong Results
Get Alerts QSII Hot Sheet
Price: $22.35 --0%
Rating Summary:
4 Buy, 15 Hold, 7 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 15 Hold, 7 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
FBR Capital maintains a 'Market Perform' on Quality Systems (NASDAQ: QSII).
FBR analyst says, "QSII is realizing the benefit of Federal Stimulus dollars and buying decisions are driving increased software sales. The company posted $0.64 of diluted EPS, a nickel ahead of our estimate and $0.03 ahead of consensus. We note that the company did post a stronger $0.06 beat last quarter and while some investors may be happy with the earnings strength posted in the quarter, we would not be surprised if there were some investors looking for a bit more considering the strength of system sales in the quarter."
For more ratings news on Quality Systems click here and for the rating history of Quality Systems click here.
Shares of Quality Systems closed at $88.76 yesterday.
FBR analyst says, "QSII is realizing the benefit of Federal Stimulus dollars and buying decisions are driving increased software sales. The company posted $0.64 of diluted EPS, a nickel ahead of our estimate and $0.03 ahead of consensus. We note that the company did post a stronger $0.06 beat last quarter and while some investors may be happy with the earnings strength posted in the quarter, we would not be surprised if there were some investors looking for a bit more considering the strength of system sales in the quarter."
For more ratings news on Quality Systems click here and for the rating history of Quality Systems click here.
Shares of Quality Systems closed at $88.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share